Tharimmune, Inc. | WebDisclosure

Basculer en Français

9480	Companies
185524	Keywords
117913	Articles
99371	Press releases

Home
Companies
Tharimmune, Inc.

PRESS RELEASE

published on 07/17/2024 at 14:30, 1 year 4 months ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Tharimmune, Inc. appoints David H. Clarke as Strategic Advisor, bringing valuable experience to enhance company's leadership and growth in inflammation and immunology therapeutics

Biotechnology Appointment Tharimmune Inc. Inflammation David H. Clarke
BRIEF

published on 07/10/2024 at 14:35, 1 year 4 months ago

Tharimmune nomme Jules Haimovitz au poste de conseiller stratégique clé

Biotechnologie Conseiller Stratégique Tharimmune Jules Haimovitz Programme Phase 2
BRIEF

published on 07/10/2024 at 14:35, 1 year 4 months ago

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

Biotechnology Strategic Advisor Tharimmune Jules Haimovitz Phase 2 Program
PRESS RELEASE

published on 07/10/2024 at 14:30, 1 year 4 months ago

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
Tharimmune, Inc. appoints Jules Haimovitz as Strategic Advisor, leveraging his biotechnology leadership and experience. The move enhances Tharimmune's clinical programs and FDA Phase 2 progress

Biotechnology Tharimmune Inc. Clinical Programs Jules Haimovitz FDA Phase 2
BRIEF

published on 06/17/2024 at 14:05, 1 year 5 months ago

Tharimmune annonce une réunion positive de type C avec la FDA pour le programme de phase 2 du TH104

FDA TH104 Essai De Phase 2 Tharimmune CBP
BRIEF

published on 06/17/2024 at 14:05, 1 year 5 months ago

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104

FDA TH104 Phase 2 Trial Tharimmune PBC
PRESS RELEASE

published on 06/17/2024 at 14:00, 1 year 5 months ago

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. receives positive FDA Type C meeting feedback for TH104 Phase 2 program, targeting pruritus in PBC patients, plans 505(b)(2) pathway for approval

FDA Feedback Tharimmune Inc TH104 Phase 2 Pruritus PBC Patients
BRIEF

published on 04/30/2024 at 14:36, 1 year 7 months ago

Tharimmune va impliquer les investisseurs lors de deux conférences majeures en mai

Biotechnologie Conférences Investisseurs Engagement Des Investisseurs Tharimmune Inflammation Et Immunologie
BRIEF

published on 04/30/2024 at 14:36, 1 year 7 months ago

Tharimmune to Engage Investors at Two Major Conferences in May

Biotechnology Investor Conferences Investor Engagement Tharimmune Inflammation And Immunology
PRESS RELEASE

published on 04/30/2024 at 14:31, 1 year 7 months ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May
Tharimmune to present at investor conferences in May 2024, showcasing developments in inflammation & immunology therapies. CEO to participate in Planet MicroCap Showcase: VEGAS 2024 & EF Hutton Annual Global Conference

Investor Conferences Tharimmune Inflammation Immunology Therapeutic Candidates

Accesswire

Published on 12/05/2025 at 18:45, 13 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 38 minutes ago

NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 58 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 1 hour 43 minutes ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 1 hour 58 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:26, 31 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 42 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 1 hour 6 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 1 hour 11 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:00, 1 hour 57 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance

Les Echos

Published on 12/05/2025 at 17:18, 1 hour 40 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 1 hour 40 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 3 hours 47 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 3 hours 47 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 4 hours 59 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE